Atlas Trials

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Clinical trial NCT04818372 · UNKNOWN

Trial details

NCT number
NCT04818372
Sponsor
Keymed Biosciences Co.Ltd
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple MyelomaLymphoma
Start date
2021-04-26
Primary completion
2023-01-01
Enrollment
87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.